Tazarotene
Brand names: Zorac (psoriasis), Twyneo (acne — newer combined formulation)
Tazarotene is a topical retinoid used for mild-to-moderate plaque psoriasis and for acne.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
As a receptor-selective retinoid it binds retinoic acid receptors to normalise keratinocyte differentiation and proliferation and exert anti-inflammatory effects in the skin.
Prescribing in practice
- Contraindicated in pregnancy and in women planning pregnancy because of the teratogenic potential of retinoids, so effective contraception is required.
- Apply sparingly to plaques only, avoiding healthy skin, flexures, the face and eyes to limit irritation.
- Skin irritation is dose-related and patients should minimise sun exposure and use sun protection.
Monitoring
No routine bloods are required; monitor for local irritation and review treatment response, and confirm pregnancy status where relevant.
Counselling the patient
- Do not use if pregnant, breastfeeding or trying to conceive, and use reliable contraception.
- Apply a thin layer to the plaques only and protect surrounding skin.
- Redness, burning and dryness are common, especially early in treatment, and sun protection should be used.
Evidence & guidelines
Topical tazarotene is an established option for localised plaque psoriasis and acne, supported by randomised controlled trial evidence.
Reference: BAD Psoriasis Guidelines 2017; BAD Acne Guidelines 2020; NICE NG198; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- PASI — Psoriasis Area and Severity Index · Diagnosis
- DLQI — Dermatology Life Quality Index · Diagnosis
- PASI Score (Psoriasis Area and Severity Index) · Psoriasis
- DLQI (Dermatology Life Quality Index) · Quality of Life
- Acne Severity Classification (IGA Scale) · Acne
- CASPAR Criteria for Psoriatic Arthritis · Diagnosis
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD